Rifampin (Rifampicin)

Subscribe to Selected New Research on Rifampin

4509 relevant articles (413 outcomes, 446 trials/studies) found for this Drug

Description: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Also Known As:

Rifampicin; Benemycin; Rifadin; Rimactan; Rimactane; Tubocin; Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-

Relationship Network

Drug Context: Research Results

Experts

1.	McIlleron, Helen: 5 articles (06/2008 - 07/2005)
2.	Ruxrungtham, Kiat: 5 articles (01/2008 - 01/2005)
3.	Ijaz, Kashef: 5 articles (02/2007 - 07/2004)
4.	Navin, Thomas R: 5 articles (02/2007 - 07/2004)
5.	Centers for Disease Control and Prevention (CDC): 5 articles (08/2003 - 03/2000)
6.	Leonildi, A: 4 articles (01/2008 - 06/2004)
7.	Gemignani, G: 4 articles (01/2008 - 06/2004)
8.	Menichetti, F: 4 articles (01/2008 - 06/2004)
9.	Manosuthi, Weerawat: 4 articles (01/2008 - 09/2005)
10.	Nagai, Hideaki: 4 articles (07/2007 - 04/2003)

Related Diseases

1.	Infection 07/01/1990 - "Rifampin cured 12 of 12 infections and was also the most efficient drug in any experimental in vitro test. " 12/01/2008 - "Peripheral blood from all dogs became PCR negative after antibiotic treatment, suggesting that these infections were eliminated and that rifampin is an effective alternative chemotherapeutic agent for treatment of CME." 11/01/1987 - "When treatment was started 3 weeks after infection, RP was inferior to rifampicin in therapeutic efficacy. " 11/01/1987 - "In particular, when treatment was started immediately after infection, RP showed a therapeutic efficacy comparable to that of rifampicin, although a double dose of the drug was required. " 11/01/1983 - "All three drugs were effective in increasing survival in 1LD50 infections, but only rifampicin gave any protection against 10LD50 infection. " Order ALL the reference details at left...
2.	Tuberculosis 11/01/2005 - "Rifampicin is one of the oldest and most effective chemotherapeutic agents available for the treatment of tuberculosis but exhibits variable bioavailability from separate and fixed dose combination formulations, which has been identified as a major bottleneck in the effective treatment of tuberculosis. " 01/01/2003 - "The drug proved to be effective in patients who isolated drug-resistant Mycobacteria tuberculosis, including those to a combination of isoniazide and rifampicin. " 05/01/1997 - "In conclusion, preventive therapy with rifampin was well tolerated and well accepted, and it appears effective in preventing active tuberculosis." 05/01/1999 - "Rifampin is a first-line drug useful in the treatment of tuberculosis. " 01/01/2009 - "Symptoms were relieved and did not recur when all the anti-tuberculosis agents except rifampicin were started again. " Order ALL the reference details at left...
3.	Pulmonary Tuberculosis 05/04/1974 - "Therapeutic efficacy of rifampin in newly detected pulmonary tuberculosis." 07/01/2005 - "Since the introduction of rifampicin, it has been believed that pulmonary tuberculosis can be cured with medication alone. " 11/01/2000 - "OBJECTIVE: To assess the efficacy of a daily, self-administered 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis (TB) in human immunodeficiency virus (HIV) infected adults. " 11/01/2000 - "Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. " 10/01/1984 - "[Relation between the efficacy of complex therapy of patients with destructive pulmonary tuberculosis and the duration of rifampicin administration]" Order ALL the reference details at left...
4.	Brucellosis (Malta Fever) 01/12/1984 - "Rifampin, which exhibits good intracellular diffusion and in vitro bactericidal activity on brucella, is effective in experimental brucellosis in mice, without selection of resistant strains. " 01/01/1990 - "It is evident from this study that the treatment with rifampicin alone is not as effective in brucellosis as it is when given with another appropriate drug." 12/01/2005 - "This study shows that the Republic of Korea is no longer free of human brucellosis, Brucella abortus biotype 1. We reviewed the patients' characteristics and serologic data during the one-year follow up period, and we also discuss on the efficacy and side effects of the rifampin and doxycyline regimen used for the treatment of human brucellosis." 08/01/2008 - "R Rifampicin resistance of Brucella melitensis by rpoB gene analysis has not yet been performed in Turkey, where brucellosis is endemic. " 12/01/2001 - "Consideration should be given to prohibiting the routine use of rifampicin for the treatment of brucellosis." Order ALL the reference details at left...
5.	Pruritus (Itching) 02/01/1988 - "Visual analogue scale pruritus scores showed no significant placebo response or any effect from the order of treatment, but did show a highly significant reduction in pruritus in response to rifampin (p less than 0.002). " 07/01/1993 - "Rifampicin appears to be effective in the treatment of refractory pruritus. " 04/01/1990 - "Rifampin proved effective in alleviating pruritus in all five children tested compared with a placebo-treated group. " 02/01/1991 - "With rifampin, pruritus disappeared in 11 patients and partially improved in three; with placebo, only two had a partial response (P less than 0.001). " 03/01/2007 - "OBJECTIVE: The present study aimed at verifying the safety and efficacy of rifampicin in ameliorating pruritus in cholestatic children. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Isoniazid (Ftivazide)
2.	Vancomycin
3.	Pyrazinamide
4.	Doxycycline (Vibramycin)
5.	Ethambutol (Myambutol)
6.	Streptomycin (Streptomycin Sulfate)
7.	Ciprofloxacin (Cipro)
8.	Erythromycin (Erycette)
9.	Ofloxacin (Levofloxacin)
10.	Minocycline (Cyclops)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Chemoprevention
4.	Prostheses and Implants (Prosthesis)
5.	Debridement

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>